Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies

Reumatismo

Volumn 66, Issue 3, 2014, Pages 215-223

  Notarnicola, A ^a,b   Lapadula, G ^a   Natuzzi, D ^a   Iannone, Florenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Idiopathic inflammatory myopathies; IL 10; IL 17 isoform A; IL 6; Interleukin (IL) 15; Macrophage inflammatory protein (MIP) 1 ; MIP 1 ; Monocyte chemoattractant protein 1

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; CYCLOSPORIN A; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE;

ADULT; AGED; ANTISYNTHETASE SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MANUAL MUSCLE TEST; PHYSICAL EXAMINATION; POLYMYOSITIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; VERY ELDERLY; BLOOD; MIDDLE AGED; MYOSITIS; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-15; INTERLEUKIN-17; MALE; MIDDLE AGED; MYOSITIS;

EID: 84908664766     PISSN: 00487449     EISSN: 22402683     Source Type: Journal    
DOI: 10.4081/reumatismo.2014.746     Document Type: Article

References (43)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362: 971-82.
2. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010; 1184: 134-53.
3. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011; 13: 209.
4. Gunawardena H, Betteridge ZE, McHugh NJ. Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol. 2008; 20: 675-80.
5. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009; 48: 607- 12.
6. Baird GS, Montine TJ. Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Arch Pathol Lab Med. 2008; 132: 232-8.
7. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009; 60: 3436-46.
8. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2009; 21: 610-6.
9. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013; 88: 83-105.
10. Kondo M, Murakawa Y, Harashima N, Kobayashi S, Yamaguchi S, Harada M. Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies. Immunology. 2009; 128: e589-99.
11. Mielnik P, Chwalinska-Sadowska H, Wiesik- Szewczyk E, Maslinski W, Olesinska M. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2012; 32: 639-43.
12. Nasr R, Reed AM, Peterson EJ. Update: biomarkers for idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2012; 24: 609-15.
13. Rayavarapu S, Coley W, Nagaraju K. An update on pathogenic mechanisms of inflammatory myopathies. Curr Opin Rheumatol. 2011; 23: 579-84.
14. Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 2012; 64: 4078-86.
15. Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006; 39: 177-90.
16. Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford). 2010; 49: 1867-77.
17. Tournadre A, Miossec P. Cytokine response in inflammatory myopathies. Curr Rheumatol Rep. 2007; 9: 286-90.
18. Tournadre A, Miossec P. Chemokines and dendritic cells in inflammatory myopathies. Ann Rheum Dis. 2009; 68: 300-4.
19. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol. 2011; 7: 297-306.
20. Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol. 2002; 14: 917-24.
21. Tournadre A, Miossec P. Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep. 2012; 14: 252-6.
22. Zong M, Loell I, Lindroos E, Nader GA, Alexanderson H, Hallengren CS, et al. Effects of immunosuppressive treatment on interleukin- 15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis. 2012; 71: 1055-63.
23. Machado Diaz AC, Chico Capote A, Arrieta Aguero CA, Rodríguez Alvarez Y, García Del Barco Herrera D, Estévez Del Toro M, et al. Proinflammatory soluble interleukin-15 receptor alpha is increased in rheumatoid arthritis. Arthritis. 2012; 2012: 943156.
24. Masuko-Hongo K, Kurokawa M, Kobata T, Nishioka K, Kato T. Effect of IL15 on T cell clonality in vitro and in the synovial fluid of patients with rheumatoid arthritis. Ann Rheum Dis. 2000; 59: 688-94.
25. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005; 7: R784-95.
26. Truchetet ME, Mossalayi MD, Boniface K. IL-17 in the rheumatologist’s line of sight. Biomed Res Int. 2013; 2013: 295132.
27. Shen H, Xia L, Lu J, Xiao W. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol. 2011; 40: 217-20.
28. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska- Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin Asensitive mechanism. J Immunol. 2000; 164: 2832-8.
29. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292: 344-7.
30. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292: 403-7.
31. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990; 77: 1019-38.
32. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003; 30: 603-17.
33. Alexanderson H, Lundberg IE, Stenström CH. Development of the myositis activities profile- -validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol. 2002; 29: 2386-92.
34. Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH. The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians. 1997; 109: 275-85.
35. Chen F, Shu XM, Wang DX, Wang GC, Lu X. [Measurement and clinical significance of serum monocyte chemoattractant protein-1 in patients with polymyosits/dermatomyosits]. Beijing Da Xue Xue Bao. 2012; 44: 204-8.
36. Chinoy H, Salway F, Fertig N, Tait BD, Oddis CV, Ollier WE, et al. Monocyte chemotactic protein-1 single nucleotide polymorphisms do not confer susceptibility for the development of adult onset polymyositis/dermatomyositis in UK Caucasians. Rheumatology (Oxford). 2007; 46: 604-7.
37. Liprandi A, Bartoli C, Figarella-Branger D, Pellissier JF, Lepidi H. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol. 1999; 97: 642-8.
38. Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol. 2000; 164: 6593-600.
39. Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H. Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol. 2001; 28: 2389-91.
40. Król P, Kryštůfková O, Polanská M, Mann H, Klein M, Beran O, et al. Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis. 2011; 70: 879-80.
41. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol. 1998; 161: 409-14.
42. Ferraccioli G, Zizzo G. The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. Discov Med. 2011; 11: 413-24.
43. Quinn LS, Haugk KL, Grabstein KH. Interleukin- 15: a novel anabolic cytokine for skeletal muscle. Endocrinology. 1995; 136: 3669-72.